Companion Diagnostics Market Outlook: Liquid Biopsy, Asia-Pacific, and AI

The companion diagnostics market is evolving toward liquid biopsy, rapid Asia-Pacific expansion, and AI-integrated interpretation. These trends will shape growth and determine how testing is delivered over the coming decade.

Liquid biopsy is a major theme. Blood-based tests such as Guardant360 CDx and FoundationOne Liquid CDx have secured FDA approvals and are seeing rapid commercial uptake — Guardant reported over 400,000 clinical tests in fiscal 2024, a 35% increase. According to companion diagnostic market analysis, liquid biopsy is a key growth driver.

Asia-Pacific expansion is the second theme. The region is growing at 13.45% CAGR, led by China's precision medicine funding and India's expanding molecular lab network.

AI is the third theme. Machine learning is being embedded into diagnostic interpretation, with AI modules increasingly included in regulatory submissions.

Challenges include IVDR compliance, reimbursement in emerging markets, and data privacy. Opportunities include liquid biopsy, Asia-Pacific expansion, and AI.

Overall, the companion diagnostics market is expected to grow substantially, with innovation and access driving the next phase.

People Also Ask

Q: What is liquid biopsy in companion diagnostics?
A: It is a blood-based test that detects tumour DNA, offering a less invasive alternative to tissue biopsy for biomarker testing.

Q: Which region is expected to grow fastest in the companion diagnostics market?
A: Asia-Pacific is expected to grow fastest at 13.45% CAGR, driven by government precision medicine funding and expanding lab infrastructure.

Tags: #MarketOutlook #CompanionDiagnostics #LiquidBiopsy #AIinDiagnostics #AsiaPacific #HealthcareInnovation

Leggi tutto